Patient‐reported outcomes from a multicenter, randomized, vehicle‐controlled clinical study of MAS063DP (Atopiclair^™) in the management of mild‐to‐moderate atopic dermatitis in adults

References

• Su J. C., Kemp A. S., Varigos G. A., Nolan T. M. Atopic eczema: Its impact on the family and financial cost. Arch Dis Child 1997; 76: 159–62
   PubMed Web of Science ®Google Scholar
• Drake L., Prendergast M., Maher R., Breneman D., Korman N., Satoi Y., et al. The impact of tacrolimus ointment on health‐related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44((1 suppl):)s65–72
   Google Scholar
• Holm E. A., Esmann S., Jemec G. B. The handicap caused by atopic dermatitis – sick leave and job avoidance. J Eur Acad Dermatol Venereol 2006; 20: 255–9
   PubMed Web of Science ®Google Scholar
• Abramovits W. Atopic dermatitis. J Am Acad Dermatol 2005; 53((1 suppl 1))s86–93
   Google Scholar
• Abramovits W. Atopic dermatitis. J Am Acad Dermatol 2005; 53((1 suppl 1))s70–7
   Google Scholar
• Tofte S. J., Hanifin J. M. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001; 44((1 suppl 1))s13–16
   Google Scholar
• Boguniewicz M., Nicol N. Conventional therapy for atopic dermatitis. Immunol Allergy Clin North Am 2002; 22: 107–24
   Google Scholar
• Ellis C., Luger T., Abeck D., Allen R., Graham‐Brown R. A., De Prost Y., et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): Clinical update and current treatment strategies. Br J Dermatol 2003; 148((suppl 63))s3–10
   PubMedGoogle Scholar
• Hanifin J. M., Cooper K. D., Ho V. C., Kang S., Krafchik B. R., Margolis D. J., et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2004; 50: 391–404
   PubMed Web of Science ®Google Scholar
• Hengge U. R., Ruzicka T., Schwartz R. A., Cork M. J. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1–15
   PubMed Web of Science ®Google Scholar
• Fleischer A. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol 1999; 104((3 part 3))s126–30
   Google Scholar
• Qureshi A. A., Fischer M. A. Topical calcineurin inhibitors for atopic dermatitis: Balancing clinical benefit and possible risks. Arch Dermatol 2006; 142: 633–57
   PubMedGoogle Scholar
• Abramovits W., Gover M. D., Gupta A. K. Atopiclair nonsteroidal cream. Skinmed 2005; 4: 369
   PubMedGoogle Scholar
• Amagaya S., Sugishita E., Ogihara Y., Ogawa S., Okada K., Aizawa T. Comparative studies of the stereoisomers of glycyrrhetinic acid on anti‐inflammatory activities. J Pharmacobiodyn 1984; 7: 923–8
   PubMedGoogle Scholar
• Bombardelli E., Curri S. B., Della Loggia R., Del Negor P., Tubaro A., Gariboldi P. Anti‐inflammatory activity of 18‐β‐glycyrrhetinic acid in Phytosome® form. Fitoterapia 1989; 60((suppl 1))s29–39
   Google Scholar
• Monder C., White P. C. 11‐beta‐hydroxysteroid dehydrogenase. Vitam Horm 1993; 47: 187–271
   PubMed Web of Science ®Google Scholar
• MacKenzie M. A., Hoefnagels W. H., Jansen R. W., Benraad T. J., Kloppenborg P. W. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J Clin Endocrinol Metab 1990; 70: 1637–43
   PubMed Web of Science ®Google Scholar
• Teelucksingh S., Mackie A. D., Burt D., McIntyre M. A., Brett L., Edwards C. R. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 1990; 335: 1060–3
   PubMed Web of Science ®Google Scholar
• Kroes B. H., Beukelman C. J., van den Berg A. J., Wolbink G. J., van Dijk H., Labadie R. P. Inhibition of human complement by beta‐glycyrrhetinic acid. Immunology 1997; 90: 115–20
   PubMed Web of Science ®Google Scholar
• Shin Y. W., Bae E. A., Lee B., Kim J. A., Kim Y. S. In vitro and in vivo antiallergic effects of Glycyrrhiza glabra and its components. Planta Med 2007; 73: 257–61
   PubMed Web of Science ®Google Scholar
• Lee Y. M., Hirota S., Jippo‐Kanemoto T., Kim H. R., Shin T. Y., Yeom Y., et al. Inhibition of histamine synthesis by glycyrrhetinic acid in mast cells cocultured with Swiss 3T3 fibroblasts. Int Arch Allergy Immunol 1996; 110: 272–7
   PubMed Web of Science ®Google Scholar
• Kang O. H., Kim J. A., Choi Y. A., Park H. J., Kim D. K., An Y. H., et al. Inhibition of interleukin‐8 production in the human colonic epithelial cell line HT‐29 by 18 beta‐glycyrrhetinic acid. Int J Mol Med 2005; 15: 981–5
   PubMed Web of Science ®Google Scholar
• Homma M., Minami M., Taniguchi C., Oka K., Morita S., Niitsuma T., et al. Inhibitory effects of lignans and flavonoids in saiboku‐to, a herbal medicine for bronchial asthma, on the release of leukotrienes from human polymorphonuclear leukocytes. Planta Med 2000; 66: 88–91
   PubMed Web of Science ®Google Scholar
• Maffei Facino R., Carini M., Aldini G., Bombardelli E., Morazzoni P., Morelli R. Free radicals scavenging action and anti‐enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung 1994; 44: 592–601
   PubMed Web of Science ®Google Scholar
• Weindl G., Schaller M., Schäfer‐Korting M., Korting H. C. Hyaluronic acid in the treatment and prevention of skin diseases: Molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol 2004; 17: 207–13
   PubMed Web of Science ®Google Scholar
• Grassi L., Moretti M., Bisetti A. Un nuovo farmaco mucoattivo con attivita' anti‐proteasica: la Telmesteina. Riv Ital Biol Med 1992; 12: 67–74
   Google Scholar
• Data on file Sinclair Pharmaceuticals Ltd, Goldalming, United Kingdom, March 2005
   Google Scholar
• Abramovits W., Boguniewicz M. A multicenter, randomized, vehicle‐controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006; 5: 236–44
   PubMedGoogle Scholar
• Hanifin J. M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980, suppl 92: 44–7
   Google Scholar
• Rajka G., Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 13–14
   PubMedGoogle Scholar
• Wahlgren C. F. Itch and atopic dermatitis: An overview. J Dermatol 1999; 26: 770–9
   PubMedGoogle Scholar
• Abeck D., Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000; 1: 41–6
   PubMedGoogle Scholar
• Kang S., Lucky A. W., Pariser D., Lawrence I., Hanifin J. M. Long‐term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: 58–64
   PubMed Web of Science ®Google Scholar
• Zuberbier T., Orlow S. J., Paller A. S., Taïeb A., Allen R., Hernanz‐Hermosa J. M., et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226–32
   PubMed Web of Science ®Google Scholar
• Charman C. R., Morris A. D., Williams H. C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931–6
   PubMed Web of Science ®Google Scholar
• Schiffner R., Schiffner‐Rohe J., Landthaler M., Stolz W. How large is the loss of effectiveness of a treatment modality between ‘theory’ and ‘practice’? An evaluation of health economics factors in a study of 1281 patients treated with ambulatory balneophototherapy. Hautarzt 2002; 53: 22–9
   PubMedGoogle Scholar
• Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol 1996; 37: 10–13
   PubMedGoogle Scholar